Abstracts Archive - Page 797 of 2607 - ACR Meeting Abstracts

Abstract Number: 1378 • ACR Convergence 2021
Presence of Anti-RNA Polymerase 3 Antibody in Systemic Sclerosis, Renal Disease, Malignancy and ILD from a Single Academic Center Cohort
Matthew Kirkpatrick¹, Janet Lee¹, Anne Tebo², Haojia Li¹, yue zhang¹ and Tracy Frech¹, ¹University of Utah, Salt Lake City, UT, ²Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: Autoantibodies are included in the disease classification criteria for systemic sclerosis (SSc). Our group previously reported the level of topoisomerase autoantibody as an important…
Abstract Number: 1379 • ACR Convergence 2021
Serum Levels of the Soluble Receptor for Advanced Glycation Endproducts Are Prospectively Associated with Pulmonary Arterial Hypertension in Systemic Sclerosis
Isabella Atzeni¹, Yehya Al-Adwi², Berber Doornbos-van der Meer², Anniek Van Roon², Caroline Roozendaal¹, Andries Smit², Alja J. Stel², Harry Van Goor², Tji-Joong Gan¹, Johanna Westra² and Douwe J Mulder², ¹University of Groningen, University Medical Centre Groningen, Groningen, Groningen, Netherlands, ²University of Groningen, University Medical Centre Groningen, Groningen, Netherlands
Background/Purpose: Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are the leading causes of death in Systemic Sclerosis (SSc). Markers for early detection of…
Abstract Number: 1380 • ACR Convergence 2021
Quality of Life in Patients with Scleroderma Associated Calcinosis Cutis: A Cross-Sectional Study
Aditi Patel¹, Mehnaj Grewal², Robert Butler² and Soumya Chatterjee³, ¹Cleveland Clinic, Cleveland Heights, OH, ²Cleveland Clinic, Cleveland, OH, ³Cleveland Clinic, Richmond Heights, OH
Background/Purpose: Calcinosis cutis (CC) can commonly affect patients with systemic sclerosis (SSc), which is often painful, resulting in functional impairment and morbidity. A radiographic scoring…
Abstract Number: 1381 • ACR Convergence 2021
Chemokines CCL2 and CCL17 as Potential Serum Biomarkers for Interstitial Lung Disease in Systemic Sclerosis
Imon Barua¹, Håvard Fretheim², Hilde Jenssen Bjørkekjær³, Henriette Didriksen⁴, Oyvind Midtvedt², Trond Mogens AAløkken², Torhild Garen⁵, Oyvind Molberg⁶, John Belperio⁷ and Anna-Maria Hoffmann-Vold¹, ¹Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ²Oslo University Hospital, Oslo, Norway, ³Department of Rheumatology, Sørlandet sykehus HF, Kristiansand, Norway, ⁴Oslo University Hospital, Moss, Norway, ⁵Department of Rheumatology, Oslo University Hospital, Oslo, Nepal, ⁶Oslo University Hospital, Oslo, Nepal, ⁷University of California Los Angeles Interstitial Lung Disease Center, Los Angeles, CA
Background/Purpose: Systemic sclerosis (SSc) carries high risk for progressive interstitial lung disease (ILD). Several anti-inflammatory therapies have been used to treat SSc-ILD and recently the…
Abstract Number: 1382 • ACR Convergence 2021
Survey on Treatment Practices in Subclinical Interstitial Lung Disease in Systemic Sclerosis
Sabrina Hoa¹, Murray Baron² and Marie Hudson³, ¹Division of Rheumatology, Centre hospitalier de l'Université de Montréal; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ²Jewish General Hospital, Montréal, QC, Canada, ³McGill University, Montréal, QC, Canada
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of mortality in systemic sclerosis (SSc). Early detection and treatment of SSc-ILD may lead to improved…
Abstract Number: 1383 • ACR Convergence 2021
Prediction of Digital Ulcers in Patients with Systemic Sclerosis Based on the Use of Platelet Inhibitors and Other Parameters – A EUSTAR Study on Derivation and Validation of a Clinical Prediction Model
Alexandru Garaiman¹, Klaus Steigmiller², Catherine Gebhard³, Marco Matucci-Cerinic⁴, Jorg Henes⁵, Jeska de Vries-Bouwstra⁶, Vanessa Smith⁷, Andrea Doria⁸, Yannick Allanore⁹, Lorenzo Dagna¹⁰, Branimir Anic¹¹, Carlomaurizio Montecucco¹², Otylia Kowal-Bielecka¹³, Mickael Martin¹⁴, Yoshiya Tanaka¹⁵, Anna-Maria Hoffmann-Vold¹⁶, Ulrike Held², Oliver Distler¹⁷ and Mike Oliver Becker¹⁸, ¹University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²Epidemiology, Biostatistics and Prevention Institute, Department of Biostatistics, University of Zurich, Zurich, Switzerland, ³Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁴University of Florence, Florence, Italy, ⁵University Hospital Tuebingen, Tuebingen, Germany, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷Department of Rheumatology and Internal Medicine, Ghent University Hospital, Ghent, Belgium, ⁸University of Padova, Padova, Italy, ⁹Université de Paris, Paris, France, ¹⁰10Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Milano, Italy, ¹¹Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, University Hospital Centre Zagreb and University of Zagreb, School of Medicine, Zagreb, Croatia, ¹²Department of Rheumatology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy, ¹³Department of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland, ¹⁴Internal Medicine, Poitiers University Hospital, Poitiers, France, ¹⁵University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁶Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ¹⁷Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland, ¹⁸Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
Background/Purpose: Digital ulcers (DUs) affect half of the patients with systemic sclerosis (SSc) and can be complicated by gangrene and amputation. Platelets are known to…
Abstract Number: 1384 • ACR Convergence 2021
A Genomic Meta-Analysis of Clinical Variables and Association with Intrinsic Molecular Subsets in Systemic Sclerosis
Jennifer Franks¹, Diana Toledo¹, Viktor Martyanov¹, Yue Wang², Suiyuan Huang³, Tammara Wood¹, Cathie Spino³, Robyn Domsic⁴, Monique Hinchcliff⁵, Dinesh Khanna³ and Michael Whitfield⁶, ¹Geisel School of Medicine at Dartmouth, Hanover, NH, ²Geisel School of Medicine at Dartmouth, West Lebanon, NH, ³University of Michigan, Ann Arbor, MI, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Yale School of Medicine, Westport, CT, ⁶Geisel School of Medicine, Lebanon, NH
Background/Purpose: Four intrinsic molecular subsets (Inflammatory, Fibroproliferative, Limited, Normal-like) have been identified in systemic sclerosis (SSc) that may have different clinical associations. To test this…
Abstract Number: 1385 • ACR Convergence 2021
Overall Survival in Patients with Systemic Autoimmune Diseases Following Lung or Heart-Lung Transplantation at a Single High-Volume Academic Transplant Center: A Comparative Cohort Study
Jason Melehani¹, Shufeng Li², Joshua Mooney³ and Lorinda Chung², ¹Stanford University, San Jose, CA, ²Stanford University, Palo Alto, CA, ³Stanford University, Stanford, CA
Background/Purpose: Lung manifestations of systemic autoimmune diseases are a frequent cause of early death. For many patients, current treatments cannot arrest the inexorable progression to…
Abstract Number: 1386 • ACR Convergence 2021
Measurement of TIMP-1 in Pulmonary Vessels May Be a Novel Marker of Reflecting mPAP in CTD-PH
Shusaku Nakashima¹, Kaori Ishikawa¹, Kiyo Ueeda¹, Tomohiro Kameda¹, Hiromi Shimada¹, Risa Wakiya¹, Mansour mai¹, Mikiya Kato¹, Taichi Miyagi², Koichi Sugihara¹, Rina Semba¹, Mao Mizusaki¹ and Hiroaki Dobashi³, ¹Kagawa University, Takamatsu, Japan, ²Kagawa University, Kidagun, Japan, ³Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan
Background/Purpose: CTD is a disease with immune abnormalities which could alter normal cytokine profile. CTD-PH has a different pathogenesis from that of iPAH, and immunosuppressive…
Abstract Number: 1387 • ACR Convergence 2021
Macrovascular Dysfunction and Its Clinical Implication in Systemic Sclerosis
Devender Bairwa¹, Chengappa Kavadichanda², sanket Shah³, Anoop Mathew¹, saikumar dunga³, Aishwarya Gopal³, Molly Mary Thabah¹ and VirSingh Negi¹, ¹Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India, ²JIPMER, Pondicherry, India, ³Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
Background/Purpose: Microvascular dysfunction is a key and determining feature of scleroderma (SSc). But contrary to earlier belief there is emerging evidence to suggest co-occurrence of…
Abstract Number: 1388 • ACR Convergence 2021
Heterogeneity of Primary and Secondary Peristalsis in Systemic Sclerosis: A New Model of Scleroderma Esophagus
John Pandolfino¹, Harris Perlman¹, Monique Hinchcliff², Mary Carns³, John Pandolfino¹, John Pandolfino¹, Chase Correia¹ and John Pandolfino¹, ¹Northwestern University, Chicago, IL, ²Yale School of Medicine, Westport, CT, ³Northwestern University Division of Rheumatology, Chicago, IL
Background/Purpose: Although esophageal dysmotility is common in systemic sclerosis (SSc), little is known regarding the pathophysiology of the motor abnormalities driving reflux severity and dysphagia.…
Abstract Number: 1389 • ACR Convergence 2021
Subclinical ILD Is Frequent and Progresses Across Different Connective Tissue Diseases
Anna-Maria Hoffmann-Vold¹, Helena Andersson², Silje Reiseter², Håvard Fretheim², Imon Barua¹, Torhild Garen³, Øyvind Midtvedt¹, Ragnar Gunnarsson², Michael Durheim², Trond Mogens AAløkken² and Øyvind Molberg¹, ¹Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ²Oslo University Hospital, Oslo, Norway, ³Department of Rheumatology, Oslo University Hospital, Oslo, Nepal
Background/Purpose: Based on the argument that symptoms-define-disease, physicians commonly apply the terms pre-clinical or sub-clinical disease to describe patients with disease-related findings, but no accompanying…
Abstract Number: 1390 • ACR Convergence 2021
A 5% Increase in Interstitial Lung Disease at 1-Year Follow-up Is Associated with Long-Term ILD Progression in Systemic Sclerosis
Alicia Hinze¹, Shreyasee Amin¹, Ashima Makol¹, Robert Vassallo¹, Cynthia Crowson² and Brian Bartholmai¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: The clinical course of interstitial lung disease (ILD) in systemic sclerosis (SSc) is highly variable. Some patients experience a progressive decline in lung function…
Abstract Number: 1391 • ACR Convergence 2021
Rituximab Is Superior to Placebo in Polymyalgia Rheumatica Patients: A Double Blind Randomized Controlled Proof of Principle Trial
Diane Marsman¹, Nathan den Broeder², Frank van den Hoogen³, Alfons den Broeder¹ and Aatke van der Maas⁴, ¹Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands, ²Radboud University Medical Centre, Nijmegen, Gelderland, Netherlands, ³Sint Maartenskliniek, Ubbergen, Gelderland, Netherlands, ⁴St Maartenskliniek, Nijmegen, Gelderland, Netherlands
Background/Purpose: Corticosteroids remain the cornerstone of polymyalgia rheumatica treatment, but their use has several disadvantages such as long treatment duration and glucocorticoid-related adverse events.1,2 Data…
Abstract Number: 1392 • ACR Convergence 2021
Assessment of a Patient Self-Report Frailty Tool in Patients with Polymyalgia Rheumatica
Sebastian Sattui, Deanna Jannat-Khah, Lindsay Lally, Sarah Lieber, Lisa Mandl and Robert Spiera, Hospital for Special Surgery, New York, NY
Background/Purpose: Frailty, a syndrome characterized by decreased physiologic reserve, is associated with chronic inflammation. We have shown a high prevalence of frailty in patients with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].